Leading Biopharmaceutical Companies Select Invitae to Develop Standardized Panel to Detect Molecular Residual Disease (MRD) in Patients with Acute Myeloid Leukemia (AML) Project aims to standardize MRD data generation, assessment and accelerate AML clinical trial programs bringing novel therapies to patients in need faster
News provided by
Share this article
Share this article
SAN FRANCISCO, Jan. 14, 2021 /PRNewswire/ Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the launch of a new project with Bristol Myers Squibb, Janssen Research & Development, LLC (Janssen), Novartis and Genentech, a member of the Roche Group, to develop a standardized panel for MRD detection in patients with AML to support clinical trial testing across multiple drug development programs. The companies are working together to standardize how MRD data is generated and assessed in clinical trials helping to better establish the clinical utility of MRD as a biomar
Health Management Associates Launches Institute on Addiction
News provided by
Share this article
Share this article
LANSING, Mich., Jan. 14, 2021 /PRNewswire/ Health Management Associates (HMA) announced today creation of the HMA Institute on Addiction (IOA), a division dedicated to supporting the national effort to build an evidence-based, patient-centered, and sustainable addiction treatment ecosystem.
HMA is home to some of the nation s foremost addiction experts. The IOA brings together HMA s vast and varied experience and expertise across all healthcare sectors into a one-stop shop for those in need of addiction consulting services. HMA is uniquely positioned to contribute to the addiction crises response in the United States, and we are committed to doing so, said Doug Elwell, chief executive officer of HMA. Our expertise spans the healthcare spectrum, and the real-world experience of our experts has been decades in the making. The Institute on Addiction pulls all o
Founding Father of Commercial Compliance Technology Named Chief Commercial Officer at H1
News provided by
Share this article
NEW YORK, Jan. 14, 2021 /PRNewswire/
H1, a global platform for the healthcare ecosystem, announced today that Marc Eigner has been named Chief Commercial Officer.
Eigner has more than 20 years of senior leadership experience within the life sciences and technology industries. Most notably, he is the co-founder of Polaris and is known as one of the founding fathers of pharmaceutical commercial compliance technology.
Marc Eigner has been named Chief Commercial Officer for H1. Marc s success as an entrepreneur and understanding of the markets we serve are an incredible asset to our team and our customers, said Ariel Katz, co-founder, and chief executive officer, H1. His empathetic leadership style aligns with our culture and values. He is both a colleague and a mentor.
Share this article
Share this article
ResearchAndMarkets.com s offering.
Global revenues from RA drug sales are expected to grow from $26.2B in 2019 to $29.1B in 2029.
The publisher projects that the global RA marketplace - which, for the purposes of this report, comprises eight major pharmaceutical markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Australia) - will grow at a compound annual growth rate (CAGR) of 1.0% over the 10-year forecast.
Global growth in the RA market will be driven by continued uptake of new products in the IL-6 and JAK inhibitor classes along with the anticipated approval and launch of four pipeline therapies. This growth will be slackened by sales erosion from biosimilars and generic tofacitinib. Over 70% of sales will come from the US; the US has a large population of RA patients (estimated 1.8M diagnosed prevalent cases in 2029) and high price tags for biologic and targeted synthetic disease modifying anti-rheumatic drugs (DMARDs).
/PRNewswire/ Protiviti has been named by Fortune to its 2021 Best Workplaces in the Bay Area list. Survey administrator Great Place to Work® considered.